Clinical Trials Directory

Trials / Completed

CompletedNCT04680143

Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Alexandria University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Detailed description

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.

Conditions

Interventions

TypeNameDescription
DRUGSystemic erythropoietin injectionSystemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Timeline

Start date
2020-09-01
Primary completion
2021-03-01
Completion
2021-03-30
First posted
2020-12-22
Last updated
2021-07-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04680143. Inclusion in this directory is not an endorsement.

Systemic Erythropoietin Injection in Patients Having Optic Atrophy (NCT04680143) · Clinical Trials Directory